{"metadata": {"organization_names": [], "person_names_verified": [], "organization_names_verified": ["glaxo group", "smithkline beecham corporation", "theravance, inc."], "topics": [], "entities_rejected": [], "person_names": [], "agreement_id": "f342e8dbe61194addc071d4a190be290ba681cccc1f232381937b01332527722", "vars": {}, "terms": ["**(**", "**)**", "**ADMINISTRATION**", "**AWARDS UNDER OTHER PLANS**", "**Acceleration**", "**Additional Shares**", "**Adjustments**", "**Amendment or Termination**", "**Appendix A**", "**Basic Limitation.**", "**Buyout Provisions**", "**CHANGE IN CONTROL**", "**Committee Composition**", "**Committee Responsibilities**", "**Committee for Non-Officer Grants**", "**Creditors\u2019 Rights**", "**DEFERRAL OF AWARDS**", "**DEFINITIONS**", "**Death of Recipient**", "**Dissolution or Liquidation**", "**ELIGIBILITY**", "**Effect of Change in Control**", "**Effective Date**", "**Elections to Receive NSOs, Restricted Shares or Stock Units**", "**Exercisability and Term**", "**Exercise Price**", "**Exercise of SARs**", "**Exercise/Pledge**", "**Exercise/Sale**", "**FOR RESTRICTED SHARES, STOCK UNITS AND PERFORMANCE CASH AWARDS**", "**FUTURE OF THE PLAN**", "**Form and Time of Settlement of Stock Units**", "**General Rule**", "**General**", "**INTRODUCTION**", "**Incentive Stock Options**", "**LIMITATION ON RIGHTS**", "**Modification or Assumption of Options**", "**Modification or Assumption of SARs**", "**Number and Terms of NSOs, Restricted Shares or Stock Units**", "**Number of Shares**", "**OPTIONS**", "**Other Forms of Payment**", "**Other Grants**", "**PAYMENT OF FEES IN SECURITIES**", "**PERFORMANCE CRITERIA**", "**PROTECTION AGAINST DILUTION**", "**Page**", "**Payment for Awards**", "**Performance Cash Awards**", "**Promissory Note**", "**RESTRICTED SHARES**", "**Regulatory Requirements**", "**Reorganizations**", "**Restricted Stock Agreement**", "**Retention Rights**", "**SAR Agreement**", "**SHARES AVAILABLE FOR GRANTS**", "**STOCK APPRECIATION RIGHTS**", "**STOCK UNITS AND PERFORMANCE CASH AWARDS**", "**Share Withholding**", "**Shares Subject to Substituted Awards**", "**Stock Option Agreement**", "**Stock Unit Agreement**", "**Stockholder Approval**", "**Stockholders\u2019 Rights**", "**Surrender of Stock**", "**THERAVANCE, INC. 2004 EQUITY INCENTIVE PLAN**", "**Term of the Plan**", "**Transferability of Awards**", "**Vesting Conditions**", "**Voting and Dividend Rights**", "**WITHHOLDING TAXES**", "**not**", "**\u201cPredecessor Plans\u201d**", "\u2019s third-party manufacturer) and validation of manufacturing processes (whether the Corporation\u2019s or the Corporation\u2019s third-party manufacturer\u2019s); initiation or completion of pre-clinical studies; clinical achievements (including initiating clinical studies; initiating enrollment, completing enrollment or enrolling particular numbers of subjects in clinical studies; completing phases of a clinical study (including the treatment phase); or announcing or presenting preliminary or final data from clinical studies; in each case, whether on particular timelines or generally); strategic partnerships or transactions (including in-licensing and out-licensing of intellectual property; establishing relationships with commercial entities with respect to the marketing, distribution and sale of the Corporation\u2019s products or development candidates (including with group purchasing organizations, distributors and other vendors); supply chain achievements (including establishing relationships with manufacturers or suppliers of component materials and manufacturers of the Corporation\u2019s products or development candidates); co-development, co-marketing, profit sharing, joint venture or other similar arrangements); financial ratios, including those measuring liquidity, activity, profitability or leverage; cost of capital or assets under management; financing and other capital raising transactions (including sales of the Corporation\u2019s equity or debt securities; factoring transactions; sales or licenses of the Corporation\u2019s assets, including its intellectual property, whether in a particular jurisdiction or territory or globally; or through partnering transactions); implementation, completion or attainment of measurable objectives with respect to research (including nominating a development candidate or initiating a new full discovery program), development, manufacturing (including initiating formulation or device development work or finalizing API or drug product processes), commercialization, development candidates, products or projects, safety, production volume levels, acquisitions and divestitures; factoring transactions; and recruiting and maintaining personnel. In the areas of development, regulatory progress and commercialization, the achievements described above performed by a third party with which the Corporation has a licensing or collaborative agreement (a \u201cPartner\u201d", "\u201c**Affiliate**\u201d", "\u201c**Award**\u201d", "\u201c**Board**\u201d", "\u201c**Change in Control**\u201d", "\u201c**Code**\u201d", "\u201c**Committee**\u201d", "\u201c**Common Stock**\u201d", "\u201c**Consultant**\u201d", "\u201c**Corporation**\u201d", "\u201c**Employee**\u201d", "\u201c**Exchange Act**\u201d", "\u201c**Exercise Price**", "\u201c**Fair Market Value**\u201d", "\u201c**IPO**\u201d", "\u201c**ISO**\u201d", "\u201c**NSO**\u201d", "\u201c**Option**\u201d", "\u201c**Optionee**\u201d", "\u201c**Outside Director**\u201d", "\u201c**Parent**\u201d", "\u201c**Participant**\u201d", "\u201c**Performance Cash Award**\u201d", "\u201c**Plan**\u201d", "\u201c**Pre-IPO Plans**\u201d", "\u201c**Restricted Share**\u201d", "\u201c**Restricted Stock Agreement**\u201d", "\u201c**SAR Agreement**\u201d", "\u201c**SAR**\u201d", "\u201c**Stock Award**\u201d", "\u201c**Stock Option Agreement**\u201d", "\u201c**Stock Unit Agreement**\u201d", "\u201c**Stock Unit**\u201d", "\u201c**Subsidiary**\u201d", "\u201c**Substitute Awards**\u201d", "\u201cGSK\u201d", "\u201cGovernance Agreement\u201d", "\u201cOriginal Directors\u201d"]}}